Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, ...
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution ...
With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the ...
In this episode of Denatured, you’ll hear from Christina Takke, managing partner at V-Bio Ventures and Mariette van der ...
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a ...
The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful ...
Last month’s FDA advisory committee meetings for therapies developed by Capricor Therapeutics and Replimune effectively ...
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate ...
Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases ...
BMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of ...
After downsizing by 50% last year, Arsenal Biosciences is again laying off employees. This time, 99 people are getting cut as ...
Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results